Literature DB >> 8712930

Determination of the 5' and 3' terminal noncoding sequences of the bi-segmented genome of the avibirnavirus infectious bursal disease virus.

F S Kibenge1, M M Nagarajan, B Qian.   

Abstract

Terminal sequences of the bi-segmented dsRNA genome of 3 different strains of infectious bursal disease virus (IBDV) were analyzed by the rapid amplification of cDNA 5' ends (5'RACE) procedure. Both segments are 85% homologous in a 32-nucleotide sequence comprising the 5' end, whereas the 3' end has a conserved pentamer. Comparison to published terminal sequences of other IBDV strains revealed high conservation between the two segments but more serotype-specific nucleotide changes (5 on segment A and 3 on segment B) in the 5' noncoding region compared to the 3' noncoding region (none on segment A and 1 on segment B).

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8712930     DOI： 10.1007/BF01718616

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  19 in total

1.  Rapid one-step characterization of recombinant vectors by direct analysis of transformed Escherichia coli colonies.

Authors:  G S Sandhu; J W Precup; B C Kline
Journal:  Biotechniques       Date:  1989 Jul-Aug       Impact factor: 1.993

2.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Observations on polymerase chain reaction amplification of infectious bursal disease virus dsRNA.

Authors:  B Qian; F S Kibenge
Journal:  J Virol Methods       Date:  1994-04       Impact factor: 2.014

4.  Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing).

Authors:  J B Antczak; R Chmelo; D J Pickup; W K Joklik
Journal:  Virology       Date:  1982-09       Impact factor: 3.616

5.  Genomic structure of the large RNA segment of infectious bursal disease virus.

Authors:  P J Hudson; N M McKern; B E Power; A A Azad
Journal:  Nucleic Acids Res       Date:  1986-06-25       Impact factor: 16.971

6.  Infectious bursal disease virus variant from commercial Leghorn pullets.

Authors:  N M Ismail; Y M Saif; W L Wigle; G B Havenstein; C Jackson
Journal:  Avian Dis       Date:  1990 Jan-Mar       Impact factor: 1.577

7.  Segment-specific and common nucleotide sequences in the noncoding regions of influenza B virus genome RNAs.

Authors:  M Y Stoeckle; M W Shaw; P W Choppin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Genome cloning and analysis of the large RNA segment (segment A) of a naturally avirulent serotype 2 infectious bursal disease virus.

Authors:  F S Kibenge; P K McKenna; J K Dybing
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

9.  Sequence of the small double-stranded RNA genomic segment of infectious bursal disease virus and its deduced 90-kDa product.

Authors:  M M Morgan; I G Macreadie; V R Harley; P J Hudson; A A Azad
Journal:  Virology       Date:  1988-03       Impact factor: 3.616

10.  Sequence analysis of infectious pancreatic necrosis virus genome segment B and its encoded VP1 protein: a putative RNA-dependent RNA polymerase lacking the Gly-Asp-Asp motif.

Authors:  R Duncan; C L Mason; E Nagy; J A Leong; P Dobos
Journal:  Virology       Date:  1991-04       Impact factor: 3.616
View more
  3 in total

1.  A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases.

Authors:  Jeremy A Bruenn
Journal:  Nucleic Acids Res       Date:  2003-04-01       Impact factor: 16.971

Review 2.  Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence.

Authors:  M M Nagarajan; F S Kibenge
Journal:  Can J Vet Res       Date:  1997-04       Impact factor: 1.310

3.  Selection of an infectious bursal disease virus mutant with increased immunogenicity following passage under humoral immune pressure.

Authors:  M M Nagarajan; F S Kibenge; A López
Journal:  Can J Vet Res       Date:  2001-04       Impact factor: 1.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.